Compare Abeona Therapeutics Inc (ABEO) vs Ally Financial Inc (ALLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ally Financial Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Ally Financial Inc trades at $44.33 (market cap $13.92B). The key difference: Ally Financial Inc is far larger — about 37.3× Abeona Therapeutics Inc's market cap, and Ally Financial Inc pays a 2.64% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ALLY | |
|---|---|---|
Market Cap | $373.32M | $13.92B |
Sector | Health | Financials |
52-Week High | $7.23 | $47.25 |
52-Week Low | $4.17 | $35.96 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ally Financial (ALLY) trades at $45.40, up 0.18% with strong analyst support (68% buy ratings) and a $54 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q3 2025-Q1 2026. Fundamentals remain solid with a P/E of 11.22 and net income margin of 14.9%, though revenue has declined from $9.2B in 2022 to $8.77B in 2025. Recent corporate developments include a $0.30 dividend payment and upcoming Q2 2026 earnings release on July 21, 2026.
ALLY presents a compelling value opportunity with attractive valuation metrics and consistent earnings outperformance. The primary investment thesis centers on the company's dominant auto lending position and shareholder returns via dividends. Key risks include revenue stagnation, macroeconomic sensitivity to interest rates, and competitive pressure from digital banking disruptors. Upside potential exists if Q2 2026 earnings meet or exceed the $1.26 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
